The news from ESMO: An immunotherapy milestone, studying young-onset cancers, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. There are no more editions this year, but you can keep up with biopharma news by signing up for STAT’s The Readout newsletter.
A status check on immunotherapies
It was 10 years ago that Keytruda and Opdivo were approved in their first indications. One of the pervading themes of this year’s ESMO was a reflection on all that the drugs have done, and all that immunotherapy still needs to achieve.
